Akcea, Ionis report positive phase 2 study results of AKCEA-ANGPTL3-LRx MD bureau2 Feb 2020 10:30 AM ISTBoston: Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. recently announced...
Novo Nordisk wins USFDA nod for oral diabetes drug Rybelsus Medical Dialogues Bureau23 Sept 2019 2:16 PM ISTNovo Nordisk did not disclose what it plans to charge for the new oral treatment, called Rybelsus, but said it would be "competitively priced" with...
Novo Nordisk Tresiba shows lower risk of hypo in adults with Type 2 Diabetes Medical Dialogues Bureau21 Sept 2019 9:30 AM IST"We are delighted that the findings of the CONCLUDE trial support what we have seen previously across the Tresiba clinical development programme,"...
Torrent Pharma, Glenmark enter agreement to market Remogliflozin under trademark Zucator in India Medical Dialogues Bureau11 July 2019 10:00 AM IST"Glenmark will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark 'Zucator' in India," Glenmark Pharma...
Novo Nordisk gets USFDA for use of Victoza to treat type 2 diabetes in pediatric patients Meghna A Singhania18 Jun 2019 4:07 PM ISTUS The U.S. Food and Drug Administration today approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with...
CDSCO Committee rejects proposal for additional Indications of Dapaglofizin Meghna A Singhania5 May 2019 12:52 PM ISTNew Delhi: British-Swedish multinational drugmaker, AstraZeneca's stride to win approval from the Indian drug regulators for the additional...
Glenmark launches SGLT2 Inhibitor Remogliflozin under brand names Remo, Remozen Meghna A Singhania30 April 2019 10:16 AM ISTGlenmark will commercialize Remogliflozin in India under the brand names 'Remo' and 'Remozen'.Mumbai: In a major relief to diabetics, Glenmark...
Diabetes Treatment: CDSCO expert panel marketing authorization Nod to Glenmark's SGLT2 Inhibitor Remogliflozin etabonate Meghna A Singhania31 March 2019 1:39 PM ISTNew Delhi: Mumbai-based Glenmark Pharmaceuticals Limited recently received the permission from the IND Committee of the Central Drugs Standard...
Setback: USFDA rejects Sanofi, Lexicon Sotagliflozin for type 1 diabetes Farhat Nasim24 March 2019 9:45 AM ISTThe decision comes about two months after an FDA advisory panel failed to reach a consensus over whether the once-daily oral drug, sotagliflozin,...
Relief to Lupin: High court removes ban its diabetes drug Gluconorm P 30 Meghna A Singhania23 Feb 2019 12:57 PM ISTThe high court has now ruled in favour of Lupin and quashed the apex court's decision to ban Lupin's anti-diabetic drug- Gluconorm P 30.New Delhi: In...
SGLT2 inhibitors can lead to serious genital infection: USFDA warning Ruby Khatun Khatun31 Aug 2018 4:50 PM ISTThe SGLT2 inhibitors approved by the FDA include Johnson and Johnson's Invokana, Eli Lilly & Co's Jardiance, as well as those from Bristol-Myers...
4 Pharma Giants face price fixing allegations on Vidagliptin: CCI starts probe Ruby Khatun Khatun15 Dec 2017 5:15 PM ISTMumbai: Trouble is mounting for 4 big pharma companies over price fixing of an anti-diabetic drug. An investigation has initiated on drug makers...
